Q2 revenues grew 14.6% YoY to | 5038 crore due to 19.8% YoY growth in domestic formulations to | 2090 crore. US revenues grew 10.1% YoY to | 1049 crore. RoW markets grew 28.2% YoY to | 828 crore. EU grew 30.0% YoY to | 247 crore. API segment grew 20.4% YoY to | 189 crore. EBITDA margins improved 266 bps YoY to 23.4% on account of a sharp drop in other expenditure amid Covid, partly offset by lower gross margins due to change in product mix. Subsequently, EBITDA grew 29.4% YoY to | 1177 crore. PAT...